Sanofi (NASDAQ:SNY) has stopped shipping its anti-cholesterol therapy Praluent, developed with Regeneron (NASDAQ:REGN), as ...

Sanofi said on Tuesday it had stopped supplying Praluent, a popular cholesterol drug jointly developed by the French ...

Sanofi (NASDAQ:SNY) announced on Tuesday that it has stopped supplying Praluent in China due to limited availability of the popular cholesterol medication.

The U.S. Court of Appeals on Wednesday stayed an order that would bar Regeneron Pharmaceuticals and Sanofi from selling their cholesterol drug Praluent.The drugmakers can continue to sell the ...

Amgen prevented Regeneron from competing on a level playing field and unfairly denied patients access to Praluent. This anticompetitive practice shut out an innovative therapy from the PCSK9 ...

Thousand Oaks, Calif.-based Amgen won a patent dispute against Paris-based Sanofi and Tarrytown, N.Y.-based Regeneron Pharmaceuticals in 2015. Amgen alleged Praluent, which Sanofi and Regeneron co ...

Approval extends treatment of Praluent to children aged 8 and older with heterozygous familial hypercholesterolemia (HeFH) News provided by Regeneron Pharmaceuticals, Inc. Mar 11, 2024, 7:00 AM ET ...

Regeneron and Sanofi's licensing deal splits profit from Praluent in the U.S. equally between the two companies, and it also requires splitting profit from overseas sales on a sliding scale that ...

Amgen prevented Regeneron from competing on a level playing field and unfairly denied patients access to Praluent. This anticompetitive practice shut out an innovative therapy from the PCSK9 ...

Amgen prevented Regeneron from competing on a level playing field and unfairly denied patients access to Praluent. This anticompetitive practice shut out an innovative therapy from the PCSK9 ...

News provided by Regeneron Pharmaceuticals, Inc. May 15, 2025, 2:02 PM ET Federal court jury found Amgen liable for violating antitrust and tort laws by using cross-therapeutic bundled rebates to ...